top of page
Reproductive & Endocrine Systems
Catecholamine synthesis and secretion
Core Principle of Catecholamine Synthesis
🧷
Catecholamines — dopamine, norepinephrine, and epinephrine — are synthesized from the amino acid tyrosine through a series of enzymatic steps.
🧷
The pathway occurs in chromaffin cells of the adrenal medulla, sympathetic postganglionic neurons, and specific brain regions (substantia nigra, locus coeruleus).
🧷
Each step is catalyzed by a specific enzyme, and the location of these enzymes determines which catecholamine is the final product.
🧷
This pathway is the molecular basis for sympathetic nervous system function and the stress response.

The Catecholamine Synthesis Pathway
📍
Tyrosine → L-DOPA (via tyrosine hydroxylase) → dopamine (via DOPA decarboxylase) → norepinephrine (via dopamine β-hydroxylase) → epinephrine (via PNMT).
📍
Tyrosine hydroxylase is the rate-limiting enzyme — it controls the overall speed of catecholamine production.
📍
The pathway occurs stepwise: neurons lacking dopamine β-hydroxylase stop at dopamine; those lacking PNMT stop at norepinephrine.
📍
Board pearl: If asked which step limits catecholamine synthesis, the answer is always tyrosine hydroxylase.

Cellular Localization of Synthesis
🔹
Tyrosine → L-DOPA → dopamine occurs in the cytoplasm.
🔹
Dopamine is then packaged into vesicles where dopamine β-hydroxylase converts it to norepinephrine.
🔹
In the adrenal medulla only, norepinephrine leaks back into the cytoplasm where PNMT converts it to epinephrine, which is then repackaged.
🔹
Board distinction: Dopamine β-hydroxylase is inside vesicles; PNMT is in the cytoplasm — this explains why only the adrenal medulla makes epinephrine (it has PNMT).

Regulation of Tyrosine Hydroxylase
⭐
Tyrosine hydroxylase activity is regulated by multiple mechanisms to match catecholamine production to physiologic demand.
⭐
Short-term regulation: end-product inhibition by catecholamines competing for the cofactor binding site.
⭐
Long-term regulation: sympathetic stimulation induces tyrosine hydroxylase gene transcription, increasing enzyme levels.
⭐
Phosphorylation by PKA, PKC, and CaMKII increases enzyme activity — this is how stress rapidly boosts catecholamine synthesis.

Cofactors and Vitamin Requirements
✅
Tyrosine hydroxylase requires tetrahydrobiopterin (BH₄) as a cofactor — deficiency causes dopamine-responsive dystonia.
✅
DOPA decarboxylase requires pyridoxal phosphate (vitamin B6) — deficiency impairs catecholamine synthesis.
✅
Dopamine β-hydroxylase requires vitamin C (ascorbic acid) and copper — scurvy can impair norepinephrine synthesis.
✅
PNMT requires S-adenosylmethionine (SAM) as a methyl donor.
✅
Board pearl: Vitamin C deficiency affects catecholamine synthesis because dopamine β-hydroxylase requires ascorbate.

Storage in Chromaffin Granules
🧠
Catecholamines are stored in specialized secretory vesicles called chromaffin granules (adrenal medulla) or dense-core vesicles (neurons).
🧠
Vesicular monoamine transporter 2 (VMAT2) actively pumps catecholamines from cytoplasm into vesicles using the proton gradient.
🧠
Storage protects catecholamines from degradation by cytoplasmic monoamine oxidase (MAO).
🧠
Reserpine depletes catecholamine stores by blocking VMAT2 — historically used as an antihypertensive but causes depression.

Co-storage with Neuropeptides
⚡
Catecholamine vesicles also contain ATP, chromogranins, neuropeptide Y, and enkephalins.
⚡
The ATP:catecholamine ratio is approximately 4:1 — ATP serves as a cotransmitter at some synapses.
⚡
Chromogranins are acidic proteins that bind catecholamines, reducing osmotic pressure and allowing concentrated storage.
⚡
These co-stored molecules are released together during exocytosis and can modulate the physiologic response.

Stimulus-Secretion Coupling
📌
Catecholamine release is triggered by membrane depolarization → voltage-gated Ca²⁺ channel opening → Ca²⁺ influx.
📌
Ca²⁺ binds to synaptotagmin on the vesicle membrane, triggering SNARE protein conformational changes.
📌
SNARE proteins (VAMP, syntaxin, SNAP-25) mediate vesicle fusion with the plasma membrane.
📌
Botulinum toxin cleaves SNARE proteins, blocking catecholamine release — this explains its use in hyperhidrosis treatment.

Adrenal Medullary Secretion
📣
The adrenal medulla functions as a modified sympathetic ganglion, receiving preganglionic cholinergic input from the splanchnic nerve.
📣
Acetylcholine from preganglionic neurons binds nicotinic receptors on chromaffin cells → depolarization → catecholamine release.
📣
The adrenal medulla secretes 80% epinephrine and 20% norepinephrine directly into the bloodstream.
📣
Board pearl: The adrenal medulla is the only source of circulating epinephrine — sympathetic neurons release only norepinephrine.

Metabolic Actions of Secreted Catecholamines
🔸
Epinephrine stimulates glycogenolysis (β₂ in liver, muscle), lipolysis (β₃ in adipose), and gluconeogenesis.
🔸
Norepinephrine primarily causes vasoconstriction (α₁) but has less metabolic effect than epinephrine.
🔸
The net effect is increased glucose and free fatty acid availability during stress — the metabolic component of fight-or-flight.
🔸
Board distinction: Epinephrine is the metabolic hormone; norepinephrine is the vasoconstrictor.

Termination of Catecholamine Signaling
🧷
Synaptic catecholamine action is terminated primarily by reuptake, not enzymatic degradation.
🧷
Norepinephrine transporter (NET) on presynaptic terminals recycles norepinephrine — blocked by TCAs and SNRIs.
🧷
Dopamine transporter (DAT) clears dopamine — blocked by cocaine and methylphenidate.
🧷
Uptake-2 (extraneuronal) transports catecholamines into surrounding cells for metabolism.
🧷
Only after reuptake does enzymatic degradation by MAO and COMT occur.

Catecholamine Metabolism
📍
Two main enzymes degrade catecholamines: monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT).
📍
MAO (on mitochondrial outer membrane) oxidatively deaminates catecholamines → aldehydes → acids.
📍
COMT (in cytoplasm) methylates the 3-hydroxyl group of the catechol ring.
📍
Final metabolites: VMA (from norepinephrine/epinephrine), HVA (from dopamine).
📍
Board pearl: Urine VMA and metanephrines are measured to diagnose pheochromocytoma.

Pheochromocytoma: Pathologic Hypersecretion
🔹
Pheochromocytoma is a catecholamine-secreting tumor of chromaffin cells, usually in the adrenal medulla.
🔹
Classic triad: episodic headaches, sweating, and palpitations with hypertension.
🔹
Diagnosis: 24-hour urine metanephrines (most sensitive) or plasma free metanephrines.
🔹
The tumor secretes catecholamines continuously but also in bursts triggered by tumor manipulation, anesthesia, or tyramine-containing foods.
🔹
Board pearl: Always give α-blockade (phenoxybenzamine) before β-blockade to prevent unopposed α-stimulation.

Neuroblastoma: Pediatric Catecholamine Tumor
⭐
Neuroblastoma arises from neural crest cells and can occur anywhere along the sympathetic chain.
⭐
Most common extracranial solid tumor in children, often presenting as an abdominal mass.
⭐
Secretes catecholamines but rarely causes hypertension — instead causes opsoclonus-myoclonus syndrome.
⭐
Diagnosis: elevated urine HVA and VMA; N-myc amplification indicates poor prognosis.
⭐
Board distinction: Pheochromocytoma causes hypertension; neuroblastoma usually does not.

Defects in Catecholamine Synthesis
✅
Tyrosine hydroxylase deficiency: autosomal recessive, presents with infantile parkinsonism, responds to L-DOPA.
✅
DOPA decarboxylase deficiency: developmental delay, oculogyric crises, autonomic dysfunction; treat with dopamine agonists.
✅
Dopamine β-hydroxylase deficiency: orthostatic hypotension, ptosis, retrograde ejaculation; treat with L-DOPS.
✅
Board clue: Orthostatic hypotension with undetectable norepinephrine but high dopamine → dopamine β-hydroxylase deficiency.

Drug Effects on Synthesis and Storage
🧠
Metyrosine inhibits tyrosine hydroxylase — used preoperatively for pheochromocytoma to deplete catecholamine stores.
🧠
Carbidopa inhibits DOPA decarboxylase peripherally (doesn't cross BBB) — combined with L-DOPA for Parkinson disease.
🧠
Reserpine blocks VMAT2 → depletes all monoamine stores → depression (historical importance).
🧠
Amphetamines reverse catecholamine transporters → massive neurotransmitter release → sympathomimetic toxicity.

Regulation by Glucocorticoids
⚡
Glucocorticoids from the adrenal cortex induce PNMT expression in the adrenal medulla.
⚡
This explains why the adrenal medulla uniquely produces epinephrine — it's bathed in high cortisol concentrations from the cortex.
⚡
The adrenal portal system carries cortisol-rich blood from cortex to medulla, maintaining PNMT expression.
⚡
Chronic stress → sustained cortisol → increased PNMT → more epinephrine production.
⚡
Board pearl: Only the adrenal medulla makes epinephrine because only it has PNMT, induced by local cortisol.

Clinical Correlation: Autonomic Testing
📌
Plasma catecholamine levels increase 2-3 fold with standing — blunted response indicates autonomic failure.
📌
Clonidine suppression test: clonidine suppresses catecholamine release in normal individuals but not from autonomous tumors.
📌
Glucagon stimulation test: glucagon triggers catecholamine release from pheochromocytoma — dangerous, rarely used.
📌
Cold pressor test: hand immersion in ice water → sympathetic activation → catecholamine release → BP rise.

Board Question Stem Patterns
📣
Episodic headaches + sweating + palpitations → pheochromocytoma → check urine/plasma metanephrines.
📣
Orthostatic hypotension + ptosis + high dopamine/low norepinephrine → dopamine β-hydroxylase deficiency.
📣
Hypertensive crisis during surgery in patient with abdominal mass → pheochromocytoma → give α-blockade first.
📣
Child with abdominal mass + opsoclonus-myoclonus → neuroblastoma → check urine VMA/HVA.
📣
Depression after antihypertensive → reserpine depleting catecholamine stores.
📣
Which enzyme is rate-limiting → tyrosine hydroxylase.
📣
Why does only adrenal medulla make epinephrine → PNMT induced by cortisol.

One-Line Recap
🔸
Catecholamine synthesis proceeds from tyrosine → L-DOPA → dopamine → norepinephrine → epinephrine via specific enzymes (rate-limited by tyrosine hydroxylase), with vesicular storage protecting against degradation, calcium-triggered exocytotic release, and termination primarily by reuptake before metabolism to VMA/HVA — disrupted in pheochromocytoma (hypersecretion) and synthesis enzyme deficiencies (hyposecretion).

bottom of page

